Completed PHASE2 INTERVENTIONAL 2-arm NCT05054725

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Sponsor: Amgen

Conditions Non-Small Cell Lung Cancer

Interventions RMC-4630 Sotorasib

Updated 20 times since 2021 Last updated: Dec 29, 2025 Started: Dec 30, 2021 Primary completion: Jul 3, 2024 Completion: Aug 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by Amgen and has accumulated 20 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

20 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2
Dec 2025 — Feb 2026 [monthly]

Completed PHASE2
Sep 2025 — Dec 2025 [monthly]

Completed PHASE2
May 2025 — Sep 2025 [monthly]

Completed PHASE2

Status: Unknown → Completed
Nov 2024 — May 2025 [monthly]

Unknown PHASE2

Status: Active Not Recruiting → Unknown

▶ Show 15 earlier versions

Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
May 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2023 — May 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Sep 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Mar 2022 — May 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Revolution Medicines, Inc.
Sanofi

Data source: Revolution Medicines, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Albuquerque, United States , Barcelona, Spain , Baton Rouge, United States , Berlin, Germany , Bethesda, United States , Blacktown, Australia , Brick, United States , Buffalo, United States , Charleston, United States and 45 more locations